"ALA-CART improves the ability of CAR-T cells to detect and attack resistant cancer cells more effectively. This could lead ...

Decoy increases effectiveness of treatment in B-cell acute lymphoblastic leukaemia B-cell Acute Lymphoblastic Leukaemia ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Older patients and those with genetic risk factors were at particularly high risk of relapse and had poorer overall survival.

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring.

Pivotal Study Design: The pivotal study entitled, “A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia ...

Get Instant Summarized Text (Gist) A new CAR-T cell therapy, ALA-CART, has been developed to enhance the effectiveness and longevity of CAR-T cells against hard-to-treat cancers. This approach ...

today announced the dosing of the first patients in its pivotal Phase 2 study evaluating WU-CART-007, a potential first-in-class, investigational, anti-CD7 CAR-T cell therapy for pediatric and ...

The study was published today in the journal Cancer Cell. "This next-generation approach, called ALA-CART (adjunctive LAT-activating CAR-T cells), optimizes CAR-T cells to more effectively ...